drugset / Trial / NCT05525234
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of thalidomide in the treatment of refractory uremic pruritus in maintenance hemodialysis patients.
Timeline
- Start
- 2022-09-15
- Primary completion
- 2022-12-31
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 50 mg | Oral |
Indications
No indication recorded.